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Background: Dendritic cell (DC)-based tumor vaccine is an 
attractive modality for the treatment of colon cancer be-
cause it has been recurred and produced few side effects in 
patients. Secretory glycoprotein 90K has been found at ele-
vated level in various cancer tissues and sera. We inves-
tigated to establish a more effective DC vaccine for the 
treatment of colon cancer in which the levels of 90K are 
elevated. Methods: We obtained the concentrated 90K from 
293T cells stably expressing 90K. DCs were cultured from 
peripheral blood monocytes, and a DC vaccine pulsed with 
tumor lysate was compared with a DC vaccine pulsed with 
90K. We measured the functional activity for CTLs by using 
IFN-γ-enzyme linked immunoabsorbent spot (ELISPOT) 
assay.  Results:  DCs pulsed with tumor lysate＋90K ex-
hibited the enhanced T cell stimulation, polarization of naïve 
T cell toward Th1. The CTLs generated by DCs pulsed with 
90K efficiently lysed HCT116 cells. The results indicate that 
90K-speicifc-CTLs can recognize 90K proteins naturally pre-
sented by colon cancer cells. Conclusion: Our study sug-
gests that 90K-specific CTLs generated by 90K-pulsed DCs 
could be useful effector cells for immunotherapy in colon 
cancer.
[Immune Network 2010;10(6):206-211]
INTRODUCTION
Dendritic  cells  (DCs)  are  potent  antigen  presenting  cells 
(APC), which are highly efficient in antigen presentation and 
stimulation  of  T  lymphocytes  (1).
    Tumor vaccines must induce an immune response capable 
of clearing and eradicating tumor cells from cancer patients 
(2,3).  Many  attempts  have  been  developed  to  induce  tu-
mor-specific  immune  responses,  including  vaccination  with 
autologous/allogeneic tumor cells, tumor-associated proteins 
or peptides, and transducing DCs with viral vectors encoding 
tumor antigens. Especially, several recent clinical trials utiliz-
ing antigen-pulsed DCs have demonstrated increased survival 
of vaccinated cancer patients, the majority of tumor vaccines, 
including  DC  vaccines,  can  effectively  induce  tumor  asso-
ciated  antigen  (TAA)-specific  immune  responses  (4,5).
  90K has been reported to be a ∼90 kDa secreted glyco-
protein  that  is  a  ligand  of  galectin-3  (formerly  known  as 
Mac-2)  (6,7).  Numerous  cell  types,  including  hematopoietic 
cells and epithelial cell, synthesize and secrete 90K, thus 90K 
is  usually  present  in  the  serum  and  other  biologic  fluids 
(6,8,9). High 90K serum levels have been detected in patients 
with  inflammatory  and  neoplastic  diseases,  such  as  chronic 
hepatitis C and B (10), breast cancer (11), gastric cancer (12) 
and lung cancer (13). Immunohistochemical analysis of 90K 
expression has revealed weak or no expression in most nor-
mal tissues and strong up-regulation in tumor cells of human 
neoplastic tissues (14). These findings suggest that 90K can 
be used as a target antigen in cancer immunotherapy. It is 
therefore expected that 90K will be a novel target molecule 
in immunotherapy of colon cancer as of other 90K-positive 
cancers.
    In  this  study,  we  investigated  the  possibility  of  im-
munotherapy for colon cancer using 90K-specific cytotoxic T 
lymphocytes (CTLs) that were stimulated in vitro by dendritic 
cells  (DCs)  pulsing  with  colon  cancer  cell  lysates  and  90K 
protein.90K-specific CTL Induction for Immunotherapy in Colon Cancer
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Figure 1. Expression of the 90K mRNA in colon cancer tissues. The 
expression of 90K was determined from extraneoplastic (Normal, N) 
and neoplastic regions (Tumor, T) in 5 patients with colon cancer by
using RT-PCR.
MATERIALS AND METHODS
This study was approved by the Institutional Review Board 
of  the  Chonnam  National  University  Hwasun  Hospital.
Cell culture
HCT8, HCT116 (human colon adenocarcinoma cell lines) and 
293T (human embryonic kidney cell lines) were maintained 
in  DMEM  medium  (Thermo Fisher  Scientific) supplemented 
with  10%  fetal  bovine  serum.
Generation of dendritic cells
Monocyte-derived  immature  dendritic  cells  (imDCs)  were 
generated  from  human  peripheral  blood  mononuclear  cells 
(PBMCs) in granulocyte macrophage-colony stimulating factor 
( G M - C S F )  a n d  i n t e r l e u k i n  4  ( I L - 4 ) .  I m D C s  ( d a y  6 )  w e r e  
pulsed for 6 hrs with antigen, and then antigen-pulsed imDCs 
were  matured  with  DC  cocktail  composed  of  IL-1β (10 
ng/ml), TNF-α (50 ng/ml), IL-6 (10 ng/ml) and PGE2 (1μg/ 
ml) for 48 hrs. To obtain a concentrated 90K supernatant, we 
established 293T cells stably expressing 90K (293T/90K cells). 
Concentrated 90K supernatant from the 293T/90K cells was 
used  to  stimulate  the  DCs  pulsed  with  the  tumor  lysate.
Immunophenotyping
CD86 and HLA-DR-Phycoerythrin or CD80, CD83 and HLA- 
ABC-conjugated with fluorescein isothiocyanate (FITC) mono-
clonal antibodies (BD Pharmningen) were used to analysis for 
immunophenotyping.  Samples  were  analyzed  using  a  flow 
cytometer  (FACSCaliber;  Becton  Dickinson).  Data  anaylsis 
used  the  CELLQUEST  software  (Becton  Dickinson).
Mixed leukocyte reaction (MLR)
Functional activity of DC was determined in the primary allo-
geneic MLR assay, using human T lymphocytes as responder 
cells. CD3＋T cells were isolated using the CD3＋T cell iso-
lation kit II (Miltenyi Biotec) from human PBMCs. The MLR 
assays were carried out in round bottomed 96-well plates to 
ensure efficient DC/T cell contact. DC were added in tripli-
cates  in  graded  doses  (10
5∼10
6  cells  per  well)  to  T  cells 
(1×10
5 cells per well) in a total volume of 200μl of a CM 
per well. Proliferation of T cells was measured by uptake of 
3H-thymidine  (1μCi/well,  5  Ci/mmol;  DuPont-NEN)  pulsed 
for 16∼18 h after 5 days in culture. The cultures were har-
vested on GF/C glass fiber filter paper (Whatman Intl. Ltd., 
Maidstone,  UK)  using  a  MACH  III  microwell  harvester 
(Tomtec,  Hamden,  CT).  Incorporation  of 
3H-thymidine  was 
determined on a Betacounter (Beckmann). The counts were 
e x p r e s s e d  a s  a  c o u n t  p e r  m i n u t e  ( c p m ) .
Enzyme-linked immunosorbent spot assay
The enzyme-linked immunosorbent spot (ELISPOT) assay for 
enumeration  of  antigen-specific,  IFN-γ- s e c r e t i n g  c e l l s  h a v e  
been followed as manuals (BD Pharmingen). The number of 
IFN-γ spots  was  enumerated  by  Immuno  Spot  Analyzers 
(Cellular Technology Ltd). Data are expressed as the mean 
number  of  IFN-γ-secreting  cells/10
5 T  c e l l s .
Cytokine release
DCs  were  grown  in  24-well  plates  at  1×10
6  cells/well. 
Following supernatants were collected and stored at −80
oC. 
IL-10, IL-12p70, IFN-γ and IL-4 concentrations were meas-
ured using ELISA kits (BD Pharmingen) according to the man-
ufacturer-provided  protocols.
RESULTS
Expression of 90K in colon cancer
RT-PCR analysis was used to examine 90K expression in hu-
man colon cancer tissues. In contrast to the adjacent normal 
colon,  which  either  lacked  detectable  90K  mRNA  or  ex-
pressed  low  levels  of  90K  mRNA,  the  colon  cancer  tissues 
from all 5 patients examined showed elevated 90K mRNA ex-
pression (Fig. 1). This suggests that the 90K protein is a pos-
sible candidate as a colon cancer associated tumor antigen.
Generation of 90K -pulsed DCs
We used FACS analysis to compare the phenotype of the tu-
mor lysate-pulsed mature DCs with the phenotype of the tu-
mor lysate＋90K supernatant (1μg/ml)-pulsed and 90K su-
pernatant (1μg/ml)-pulsed mature DCs, and we found that 
both DCs exhibited high expression of CD80, CD83, CD86, 90K-specific CTL Induction for Immunotherapy in Colon Cancer
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Figure 2. Immunophenotype of DCs pulsed with antigens. Comparison of phenotypes of immature DC, unpulsed mDCs, tumor lysate- pulsed 
DCs, tumor lysate＋90K-pulsed DCs and 90K-pulsed DCs. Immature DCs were obtained by culturing peripheral blood mononuclear cells (PBMCs)
of healthy donors with IL-4 and GM-CSF. A DC cytokine cocktail was then added to the culture, and the cells were incubated for 48 hours 
to enable the immature cells to differentiate into mature DCs. Data shown as mean fluorescence intensity (MFI) increase over isotype control±with
SD from three independent experiments.
HLA-ABC, and DR, which was characteristic of mature DCs 
(Fig.  2).
T cell proliferation
The ability of DCs to induce T cell proliferation in the mixed 
lymphocyte reaction (MLR) has been commonly used to eval-
uate  their  function.  Therefore,  we  examined  DC-induced 
CD3＋T  cell  proliferation.
  In the group of DCs sensitized with tumor lysates, T cell 
p r o l i f e r a t i o n  r a t e  w a s  3 . 4 7 ;  t h e  T  c e l l  g r o u p  w i t h o u t  s t i m -
ulation  by  DCs  was  used  as  the  control  (Fig.  3).  And  the 
group of DCs sensitized with 90K sup resulted in a lower pro-
liferation index than tumor lysate did. On the other hand, in 
the DC group treated with tumor lysate＋90K, the absorption 
rate was 7.29. This result indicates that addition of 90K in-
creased  the  potential  of  DCs  as  T  cell  stimulators.
Measurement of cytokines
DCs activate T cells and regulate their differentiation into T 
helper cells type 1 (Th1) and/or T helper cells type 2 (Th2). 
So, we estimated the polarization of naive T cells toward the 
Th1 or Th2 subset by DCs pulsed with tumor lysate＋90K. 
High IL-12p70 and IFN-γ levels induce the differentiation in-
to  Th1  cells.  The  concentrations  of  IL12p70  were  6.5,  9.8, 90K-specific CTL Induction for Immunotherapy in Colon Cancer
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Figure 3. Proliferation of allogeneic T cells stimulated with DCs pulsed by antigen. T cells were stimulated with DCs pulsed tumor lysate, tumor
lysate＋90K sup and 90K. T cells only were used as a negative control. DCs were co-cultured with 1×10
5 allogeneic T cells/well in 96-well 
plates for 5 days. Then, 1μl Ci of 
3H-thymidine was added to each well, and the cells were incubated for 16∼18 hours before harvesting.
T-cell proliferation was measured by 
3[H]-thymidine uptake.
Figure 4. Cytokine secretion assay. (A) DC function estimated by the IL-12p70 assay. Supernatants from tumor lysate-pulsed DCs and tumor
lysate＋90K-pulsed DCs were examined for the secretion of IL-10 and IL-12p70 by ELISA. (B) Generation of IFN-γ-producing naïve T cells 
coculturing with DCs. Naïve T cells stimulated by co-culture with tumor lysate-pulsed DCs and tumor lysate＋90K-pulsed DCs were analyzed
for the production of IL-4 and IFN-γ by ELISA.90K-specific CTL Induction for Immunotherapy in Colon Cancer
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Figure 5. Production of IFN-γ-secreting cells from autologous CD8＋
T cells. (A) IFN-γ-secreting cells were enumerated by the ELISPOT 
assay, and the results are given as the mean number of spots and SD
per 1×10
5 T cells. T cells stimulated with HCT116 tumor lysate- 
pulsed DCs, tumor lysate＋90K pulsed-DCs and 90K pulsed-DCs were
cocultured with HCT8 or HCT116 cells in a 96-well plate for 24 hours
at 37
oC. Unprimed T cells (CTLs only) were used as the negative 
control. The results are illustrated as the mean values (with SD) of
triplicate culture in two independent experiments. (B) Differential 
expression of the 90K mRNA in colon cancer cells were examined
by RT-PCR.
and 21.2 pg/ml in the DC single group, tumor lysate-pulsed 
DC  group,  and  tumor  lysate＋90K-pulsed  DC  group,  re-
spectively  (Fig.  4A).
    Tumor lysate-pulsed DCs induced high IFN-γ production 
by T cells with minimal or no Th2 cytokine production. At 
day 7, the concentrations of IFN-γ were 1.9, 87.7, and 170.8 
in the T cells stimulated with DCs, tumor lysate-pulsed DC 
group, and tumor lysate＋90K pulsed DCs, respectively (Fig. 
4 B ) .  T  c e l l s  s t i m u l a t e d  w i t h  t u m o r  l y s a t e＋90K-pulsed  DCs 
produced  significantly  higher  levels  of  IFN-γ than  those 
pulsed  with  tumor  lysate  alone.  This  result  indicates  that 
IL-12p70  and  IFN-γ p r o d u c t i o n  w a s  i n c r e a s e d  s i g n i f i c a n t l y  
with  tumor  lysate  treatment  in  the  presence  of  90K.
Comparison of cytotoxicity
Tumor  lysate-induced  IFN-γ secretion  by  cytotoxic  T  cells 
(CTLs)  is  often  determined  by  enzyme-linked  immunospot 
(ELISPOT) assay and used as an immunological correlate of 
cytotoxic  activity.
    To  generate  antigen-specific  CTLs  from  healthy  donors, 
DCs  pulsed  with  different  antigens  were  used  as  anti-
gen-presenting cells (APCs). CTLs were co-cultured with the 
target HCT8 or HCT116 cells, and their specific responses to 
antigens were examined by ELISPOT. HCT8 cells were used 
as target control cells, because of detection of low level 90K. 
The  number of  IFN-γ-secreting cells  were  increased  about 
ten-fold  among  CTLs  stimulated  with  tumor  lysate＋90K- 
pulsed DCs, against HCT116 cells than among those stimu-
l a t e d  w i t h  t u m o r  l y s a t e - p u l s e d  D C s  ( F i g .  5 ) .  E s p e c i a l l y ,  T  
cells  stimulated  with  90K-pulsed  DCs  exhibited  the  highest 
amount among the CTL stimulated with antigen loaded DCs. 
The results indicate that the 90K protein can induce a strong 
antigen-specific  CTL  response.
DISCUSSION
DCs  are  potent  antigen-presenting  cells  able  to  induce  pri-
mary immune responses. DCs capture and process antigens 
into peptides (15-18). DCs then present the antigens to T cells 
and B cells through MHC class I and II molecules. Peptides, 
proteins, DNA and RNA coding these antigens and tumor ly-
sate have been used to sensitize DCs. An alternative approach 
to increasing antitumor immunity is the use of fusions of DCs 
and tumor cells. In this study, we demonstrated that 90K was 
highly expressed in colon cancer, indicating that 90K might 
be a possible candidate as a tumor associated antigen in co-
lon cancer. CTLs that were stimulated by 90K-pulsed DCs dis-
played high  secretion of IFN-γ against HCT116 cells com-
pared to those stimulated by tumor lysate-pulsed DCs (Fig. 
5). These results demonstrated that the CTLs were efficiently 
able  to  lyse  colon  cancer  cells  positive  for  90K  molecules.
    The finding that 90K is expressed in normal tissues such 
as breast, lung, ovary, stomach, colon, and bladder indicates 
the  possibility  of  damage  to  normal  tissues  by  immunothe-
rapy targeting 90K (8). Even though the expression level is 
l o w  i n  n o r m a l  t i s s u e ,  w e  n e e d  t o  p r o v e  t h e  r e a c t i v i t y  a n d  
impact of 90K-specific CTLs on normal tissues. Also, 90K is 
able to enhance not only induction of 90K-specific CTL but 
also the functionality of DCs. So, we need the further studies 
about possibility that 90K may have potential to enhance the 
DC function by activation the downstream signaling cascades 
associated  with  DC  maturation.90K-specific CTL Induction for Immunotherapy in Colon Cancer
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    In conclusion, our study suggests that 90K has the potential 
to be a novel target molecule in the immunotherapy of colon 
cancer  using  90K-specific  cytotoxic  T  lymphocytes.
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